COMPANY PROFILE

Desentum

Explore full profile

Biopharma company in Finland developing allergy vaccines that change the way the immune system reacts to allergens

Espoo, FinlandFounded 2011Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Desentum

Desentum is a research-oriented, clinical-stage biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching the immune system’s response to allergens from hypersensitivity to tolerance. The goal is to provide long-term relief for patients suffering from allergic symptoms. Desentum’s product development targets both aeroallergens and food allergens.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Espoo, Finland
Employees: 12
Open positions: None listed
Dealroom signal: 76.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Vaccines, Allergy, Immune System, Spinout, Biotech and Pharma, Woman Founder, Horizon Europe, DT and LS
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Apr 2026	$20M	$79M	Undisclosed	↗
EARLY VCOther financing	Feb 2024	$13M	$53M	Springvest	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	Margin
2026
2025
2024
2023
2022	—
2021	—	—
2020	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Desentum website traffic

Latest recorded traffic for Desentum is 1.6K monthly website visits, up 122.2% over the last three months. Desentum's team grew 0% over the past year.

Latest monthly visits1.6K 3-month web change+122.2% 1-year team growth0%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BIBioNTechDevelops personalized immunotherapies with a focus on cancer medicine	Mainz, Germany	Operational	5,211	$1.7B	$9.1B
SPSpyBiotechNovel vaccine platform using protein superglue technology	Oxford, United Kingdom	Operational
ATAmal TherapeuticsDeveloping and progressing therapeutic cancer vaccines	Geneva, Switzerland	Acquired
PUPulmobioticsDiscovers and develops novel treatments and vaccines for respiratory diseases	Barcelona, Spain	Operational
IOiOncturaOncology therapies countering immunosuppression in tumors	Geneva, Switzerland	Operational
IMIMMUNETHEPBiotech start-up company that is developing broad coverage anti-bacterial immunotherapies	Cantanhede, Portugal	Operational
VTValo TherapeuticsAn immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines	Helsinki, Finland	Operational
IMImmuneedDeveloping a new generation of prostate cancer vaccines, based on activation of the body's own immune system	Uppsala kommun, Sweden	Acquired